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CASE REPORT
Arthritis as an initial presentation 
of malignancy: two case reports
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Abstract 
Background: Arthritis is rarely reported as a paraneoplastic manifestation of occult malignancy. We report herein 
two cases of paraneoplastic arthritis due to occult malignancy.
Case 1: The patient was a 65-year-old woman of asian descent who was a former smoker with a history of spine 
surgery performed for L4/L5 degenerative disc disease. She presented with a 1-month history of oligoarthritis affect-
ing both ankle joints and early morning stiffness of about 3 hours. Laboratory tests were positive for antinuclear 
antibody at a titer of 1:320 (speckled) but  negative for rheumatoid factor. She was treated for seronegative spondy-
loarthritis and started on prednisolone without much improvement. A routine chest radiograph incidentally revealed 
a right lung mass which was found to be adenocarcinoma of the lung. She was treated with gefitinib and her arthritis 
resolved.
Case 2: The patient was a 64-year-old woman of asian descent, nonsmoker, who presented with a chief complaint 
of asymmetrical polyarthritis involving her right wrist, second and third metacarpophalangeal joints, and first to fifth 
proximal interphalangeal joints. She was treated for seronegative rheumatoid arthritis (RA) and started on sulfasala-
zine, with poor clinical response. Six months later, she developed abdominal pain which was diagnosed as ovarian 
carcinoma by laparotomy. Her arthritis resolved following treatment of her malignancy with chemotherapy.
Conclusion: In summary, paraneoplastic arthritis usually presents in an atypical manner and responds poorly to 
disease-modifying antirheumatic drugs. Accordingly, we recommend screening for occult malignancy in patients 
presenting with atypical arthritis.
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Background
Paraneoplastic syndromes are a collection of signs and 
symptoms caused by organ or tissue damage occurring at 
locations distant from primary tumors [1]. These symp-
toms may develop before, concurrent with, or after the 
diagnosis of a malignancy [2]. Interestingly, malignan-
cies have been associated with a wide variety of paraneo-
plastic rheumatic manifestations which may develop in 
joints, fascia, muscles, vessels or bones, often mimicking 
the presentation of primary rheumatic diseases such as 
spondyloarthropathy (SpA), rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE) or vasculitis [2]. We 
report two patients whose cases were initially diagnosed 
and treated as rheumatic diseases but were later found to 
be paraneoplastic arthritis related to malignancy.
Case presentation
Case 1
The patient was a 65-year-old woman of asian descent 
who was a former smoker for 20 years and had a his-
tory of spine surgery for L4/L5 degenerative disc disease. 
Open Access
*Correspondence:  jatirmizi@unimas.my
2 Department of Radiology, Faculty of Medicine and Health Sciences, 
University Malaysia Sarawak, Kota Samarahan, Malaysia
Full list of author information is available at the end of the article
Page 2 of 5Sachdev Manjit Singh et al. J Med Case Reports           (2021) 15:94 
She was a retiree and a nondrinker. She presented with 
a 1-month history of oligoarthritis affecting both ankle 
joints associated with early morning stiffness of about 3 
hours. On physical examination, the patient had swell-
ing and tenderness of both ankle joints, with no other 
significant findings. She had no significant family his-
tory of malignancy or inflammatory arthritis. Laboratory 
tests were negative for rheumatoid factor (RF) but posi-
tive for antinuclear  antibody (ANA) at a titer of 1:320 
(speckled pattern). Erythrocyte sedimentation rate (ESR) 
was 61 mm/hour. Accordingly, she was treated for SpA, 
for which she was started on prednisolone 10  mg once 
daily and sulfasalazine (SSZ) 500  mg twice a day, with-
out much improvement. Her SSZ was however withheld 
during a later clinic visit, as she developed macular rash 
after her dosage was increased to 1 g once daily. A rou-
tine chest radiograph (Fig. 1) performed on her first visit 
incidentally revealed a right lung mass. Subsequent con-
trast-enhanced computed tomography (CT) of the thorax 
(Fig. 2) showed a lung mass at the posterobasal segment 
of the right lower lobe measuring 4.7 × 7.0 × 7.0  cm 
(anteroposterior × width × craniocaudal). There were 
also satellite nodules adjacent to the mass. The mass was 
biopsied via bronchoscopy, and histopathological exami-
nation (HPE) results showed an adenocarcinoma favor-
ing a primary lung malignancy, which showed a deletion 
in exon 19 of the epidermal growth factor receptor 
(EGFR) gene. Therefore, she was treated with tablet gefi-
tinib 250 mg daily by the oncology team. The swelling of 
both ankles resolved with the initiation of gefitinib for 
her malignancy, with no recurrence on subsequent fol-
low-up visits to the rheumatology clinic over the next 6 
months. She was able to ambulate without any difficulty 
or pain. Her final diagnosis was revised to paraneoplastic 
arthritis secondary to adenocarcinoma of the lung. She 
was discharged to continue follow-up under the oncology 
team for her malignancy.
Case 2
The patient was a 64-year-old woman of asian descent 
who was a nonsmoker, nondrinker and known to have 
hypertension, diabetes mellitus, dyslipidemia and 
ischemic heart disease. She was a retiree and was previ-
ously on the following medications: metformin 500  mg 
once daily, amlodipine 10  mg daily, atenolol 100  mg 
daily, isosorbide dinitrate 10 mg three times a day, aspi-
rin 75 mg once a day, simvastatin 10 mg once daily and 
perindopril 2  mg daily. She presented with a 4-month 
history of asymmetrical polyarthritis involving her right 
wrist, second and third metacarpophalangeal joints 
(MCPJ), and first to fifth proximal interphalangeal joints 
(PIPJ) associated with loss of appetite and loss of weight. 
She however denied other constitutional symptoms. She 
had no family history of malignancy or connective tissue 
disease. Examination revealed swollen and tender joints 
involving her right wrist, second and third MCPJ and 
first to fifth PIPJ. There were no other significant physical 
findings on examination. Her routine laboratory workup 
was unremarkable aside from a raised ESR and positive 
antinuclear antibody at a titer of 1:160 (centromere pat-
tern). Rheumatoid factor (RF) was negative, and a routine 
chest radiograph was unremarkable. X-rays of the hands 
Fig. 1 Chest X-ray (posteroanterior erect view) with mass over the 
right lower lobe
Fig. 2 Sagittal computed tomography scan of the thorax 
demonstrates mass at the right lower lobe with associated 
surrounding satellite nodules (arrows)
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showed arthritis changes in both hands, possibly RA. 
She was treated as seronegative RA and started on SSZ 
500  mg  twice  daily and prednisolone 5  mg once daily, 
with poor clinical response. Six months after her initial 
arthritis, she presented to a private center with com-
plaints of abdominal pain, resulting in a mini-laparotomy 
with omental biopsy. The omental HPE was reported as 
metastatic deposits of grade II serous cystadenocarci-
noma of the ovary in the omentum. She was diagnosed 
with stage IIIc ovarian carcinoma and started neoadju-
vant chemotherapy with intravenous administration of 
carboplatin AUC (area under the curve) 5 at day 1, with 
paclitaxel 80  mg/m2 on days 1, 8 and 15 for six cycles 
every 21 days. Her SSZ was withheld. After three cycles 
of chemotherapy, she developed new respiratory symp-
toms. A repeat CT of the thorax/abdomen revealed a left 
apico-posterior lung mass with multiple bilateral lung 
nodules, with an ill-defined hypodense mass at the region 
of the uterine fundus (Figs. 3, 4). This was followed by a 
rigid bronchoscopy revealing a pedunculated tumor from 
the left upper lobe almost completely occluding the dis-
tal left main bronchus, which was biopsied. The biopsy 
showed a malignant tumor with sarcomatoid features. 
She proceeded to complete the six cycles of carbopl-
atin/paclitaxel. A CT reassessment post-carboplatin/
paclitaxel showed disease progression, as evidenced by a 
larger left lung mass on CT. She was then given second-
line chemotherapy consisting of gemcitabine 1400  mg 
intravenously on day 1 and day 8, planned for three cycles 
and reassessment of response. Hence, her final diagnosis 
by the oncology team was dual malignancy (stage IIIc 
ovarian serous cystadenocarcinoma and malignant 
tumor with sarcomatoid features of the left lung). During 
all her follow-up visits with the oncology team she was 
noted to have no recurrence of her polyarthritis but was 
poorly responsive to her chemotherapy, with progres-
sive respiratory symptoms. About 1 year after the initial 
diagnosis of polyarthritis, the patient succumbed to her 
illness after an admission for pneumonia.
Discussion
In both patients described above, the symptoms of 
inflammatory arthritis preceded the detection of malig-
nancy. Our first patient was a 65-year-old woman who 
presented with oligoarthritis of the ankle joints which 
was treated as SpA. The second patient presented with 
asymmetrical polyarthritis, which was treated as seron-
egative RA. Both our patients had poor clinical response 
to disease-modifying antirheumatic drugs (DMARDs) 
and were later found to have malignancy that was ade-
nocarcinoma of the lung in the first patient and ovarian 
carcinoma in the second patient. In both patients, their 
arthritis resolved only after therapy for their malignancy 
was initiated.
Arthritis is a common symptom encountered by the 
rheumatologist, with a broad range of causes includ-
ing RA, SpA, vasculitis, connective tissue diseases, 
crystal arthropathies and infections. It is however an 
uncommon presentation of paraneoplastic syndrome. 
Fig. 3 Coronal computed tomography scan image demonstrating 
uterine mass infiltrating the adjacent bowels and omentum (blue 
arrows)
Fig. 4 Sagittal computed tomography scan image demonstrating 
uterine fundus mass which has poor demarcation with the uterus 
inferiorly (arrow)
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Paraneoplastic syndromes, which include paraneoplas-
tic arthritis, may precede or occur during the course 
of malignant disease [2–4]. They should not arise from 
direct tumor invasion or compression, and usually 
improve with treatment of the underlying malignancy 
[3, 4]. Paraneoplastic arthritis itself is an inflammatory 
polyarthritis which may be seronegative [5]. It has a 
male predominance, with an average age of onset of 54 
years [5]. The arthritis is typically asymmetrical, com-
monly affecting the lower extremity joints, and may 
occur about 8–12 months prior to malignancy devel-
opment [1, 3–5]. It is usually poorly responsive to the 
standard therapy of DMARDs, corticosteroids or non-
steroidal anti-inflammatory drugs (NSAIDs) [1, 3–5]. 
Malignancies associated with paraneoplastic arthritis 
include lung, breast, ovarian, laryngeal and gastroin-
testinal tumors [2–4]. The pathogenesis is not known, 
but mediators such as cytotoxic lymphocytes, antibod-
ies, peptides, hormones and cytokines have been impli-
cated [4, 6]
According to Zupancic et al., paraneoplastic arthritis 
can be difficult to diagnose in the absence of a known 
malignancy [4]. This difficulty is illustrated by the two 
cases discussed above, where the symptoms of arthri-
tis preceded the detection of malignancy. Similar to 
other reports, both our patients presented with symp-
toms suggestive of an inflammatory arthritis which 
were subsequently diagnosed and treated as rheumatic 
diseases [4]. In the first patient, the malignancy was 
found following and abnormal routine chest radio-
graph. Similarly, for the second patient, the malignancy 
only became apparent after the patient presented with 
abdominal pain requiring surgical intervention, result-
ing in the diagnosis of a stage IIIc ovarian carcinoma.
Finally, both our patients exhibited poor response to 
DMARDs and showed improvement after treatment 
of their underlying malignancy, leading to the suspi-
cion of paraneoplastic arthritis. This poor response to 
DMARDs and improvement with antineoplastic therapy 
was described by both Briones et al. and Zupancic et al. 
in two different case reports [3, 4]. Briones described a 
patient who presented with polyarthritis and responded 
poorly to glucocorticoid therapy and was subsequently 
diagnosed with lingual carcinoma. The patient was 
treated with antineoplastic therapy, leading to progres-
sive resolution of the arthritis [3]. Similarly, Zupancic 
described a patient with a history of migratory inflamma-
tory asymmetric polyarthritis which responded poorly to 
prednisolone. The patient was subsequently diagnosed 
with small cell lung carcinoma, and arthritis symptoms 
resolved with treatment of the malignancy [4]. Hence, 
it is important that occult malignancy be suspected as 
a cause of arthritis in a patient who responds poorly to 
DMARD therapy.
Conclusion
In conclusion, paraneoplastic arthritis is a rare initial 
presentation of malignancy. The presence of arthritis in 
the absence of a known malignancy can be easily con-
fused with a primary rheumatic condition. This ulti-
mately leads to a delay in the diagnosis of an underlying 
primary malignancy. Hence, it is important to con-
sider paraneoplastic arthritis in patients who present 
atypically, develop constitutional symptoms or respond 
poorly to standard DMARD therapy.
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